

EKF Diagnostics Holdings plc
("EKF" or the "Company")

Cancellation of Treasury Shares & TVR

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, refers to its announcement dated 13 May 2025, in connection with the completion of the Company's share buyback programme of 4,636,774 ordinary shares of 1p each in the capital of the Company ("**Ordinary Shares**"). The Company confirms that these Ordinary Shares, alongside all other Ordinary Shares previously held in treasury, have now been cancelled with effect from 24 June 2025, in accordance with the provisions of section 729 of the Companies Act 2006 (the "**Cancellation**").

Further to the announcement dated 21 May 2025 in connection with an additional share buyback programme, the Company confirms that it continues to seek to conduct additional on-market purchases of Ordinary Shares of up to a further c.£1.0m, pursuant to the authorities obtained at the Company's last annual general meeting held on 20 May 2025. Any Ordinary Shares repurchased will be held in treasury.

Further details in connection with the Cancellation can be found below:

Date of Cancellation	24 June 2025
Number of Ordinary Shares cancelled pursuant to the share buyback programme	4,636,774
Number of remaining Ordinary Shares held in treasury cancelled	1,200,000
Total number of Ordinary Shares cancelled	5,836,774

Following Cancellation, the Company's total issued share capital consists of 449,093,790 Ordinary Shares with one voting right per share. The Company will not hold any Ordinary Shares in treasury.

Therefore, the total number of voting rights in the Company will be of 449,093,790.

The above figure of 449,093,790 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

EKF Diagnostics Holdings plc
Julian Baines, Executive Chair
Gavin Jones, Chief Executive Officer

www.ekfdiagnostics.com
Via Walbrook PR

Tel: +44 (0)20 7496 3000

Singer Capital Markets (Nominated Adviser & Broker)
Phil Davies / Oliver Platts

Walbrook PR Limited
Paul McManus / Alice Woodings

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654



About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is an AIM-listed global diagnostics business focussed on:

- **Point-of-Care** analysers in the key areas of Hematology and Diabetes.
- **Life Sciences** services provide specialist manufacture of enzymes and custom products for use in diagnostic food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCKZGZVGKKGKZM